A large retrospective study evaluated 160 patients who received FDA-approved CD19 CAR-T and identified grade 3/4 CRS, grade 3/4 ICANS, a higher cumulative dose of glucocorticoids in the first 30 days, and administration of anakinra as independent risk factors for herpesvirus reactivation [10]. Here, CD19 is linked to congenital rubella syndrome.